This article is more than 5 years old. Information may no longer be current.

Allergan nets $249.4 million in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Allergan reported net earnings of $249.4 million for the third quarter, compared to third-quarter earnings of $249.8 million last year, according to a news release.

"We were pleased to mark the opening of our new R&D facility in New Jersey, as well as to announce the expansion of our relationship with Molecular Partners," David E.I. Pyott, Allergan's board chairman, president and CEO, said in the release.

In August, Allergan and Molecular Partners announced two partnerships to discover, develop and commercialize designed ankyrin repeat protein (DARPin) products for the treatment of serious ophthalmic diseases.

Allergan generated $1.41 billion in revenue for the third quarter, up from $1.33 billion in the same quarter last year. Third-quarter operating income increased from $344.4 million in 2011 to $354 million this year.